China’s biotechnology sector is on track for a record year in outbound licensing deals in 2026, as global pharmaceutical companies race to secure rights to promising Chinese-developed drugs, according to industry data and analysts.
The total disclosed value of licensing-out deals from the greater China region surged to $137.7 billion in 2025, nearly ten times the level recorded in 2021, data from healthcare analytics firm Pharmcube showed. Analysts expect deal value to climb further this year as the country’s experimental drug pipeline continues to expand.
As of early 2026, dozens of outbound licensing agreements have already been announced, with average deal sizes rising sharply compared to last year. The increase reflects stronger global demand for Chinese-originated drug candidates, particularly in oncology and next-generation therapies.
Major multinational drugmakers have been active in signing large agreements with Chinese biotech firms. Recent transactions include multibillion-dollar partnerships involving leading global pharmaceutical companies seeking rights to develop and commercialize experimental Chinese treatments outside China.
Under licensing arrangements, Chinese biotech firms grant overseas partners rights to develop, manufacture or sell their drug candidates in global markets. In return, they receive upfront payments, milestone-based compensation and potential royalties. The model allows international pharmaceutical companies to diversify pipelines while reducing early-stage research risks.
Industry executives say China has evolved from being largely a producer of generic medicines to becoming a significant source of innovative drug research. Chinese biotech firms have made advances in areas such as antibody-drug conjugates and other targeted therapies, drawing attention from global investors and strategic partners.
Investment bankers expect strong momentum in cross-border licensing activity over the next 12 to 24 months as multinational drugmakers continue to seek competitive access to high-potential assets developed in China.
The surge in outbound deals underscores China’s growing role in global pharmaceutical innovation and signals a shift in research and development dynamics, with Western drugmakers increasingly looking eastward for new growth opportunities.